Cervical acid phosphatase: A biomarker of cervical dysplasia and a potential surrogate endpoint for colposcopy

Disease Markers

Volumn 19, Issue 6, 2003, Pages 279-286

  Markovic, Olivera ^a   Markovic, Nenad ^a  

^a BioSciCon Inc   (United States)

Author keywords

Acid phosphatase; Biomarker; Cancer prevention; Cervical cancer; in vitro diagnostics; Medical device; Pap test; Surrogate endpoint

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATASE;

ANALYTIC METHOD; CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; COLPOSCOPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; EPITHELIUM CELL; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MEASUREMENT; PAPANICOLAOU TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TECHNIQUE; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

EID: 3042765716     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/845798     Document Type: Review

References (24)

1. American Cancer Society: New Guideline for Early Detection of Cervical Cancer, CA Caner I Clin 52 (2001), 342-362.
2. CDC Report: Incidence of Pap Test abnormalities Within 3 Years of a Normal Pap Test - United states, 1991-1998. M
3. Cytyc Corp Home Page (http://www.thinprep.com).
4. Digene Home Page (http://www.digene.com).
5. TriPath Imaging Home Page (http://www.tripathimaging. com).
6. S.G. Malvi and S.M. Sirsat, A cytochemical study of acid phosphatase in carcinoma of the cervix uteri, The Indian Journal of Cancer 11 (1974), 81-87.
7. S.J. Gross and G. Kinzie, Cytochemistry of benign and malignant squamous epithelium of the cervix uteri, Obst. and Gynecol. 15 (1960), 261-279.
8. A. Panazzolo, L Bergantino and S. Arrotta et al., Gli enzimi lisosomiali nella patologia neoplastica del collo dell'utero, Min. Gin. 30 (1978), 1123-1145, (Italian).
9. N. Markovic and O. Markovic, CAP-PAP Test, USPTO No. 6,143,512 (November 2000).
10. O. Markovic and N. Markovic, May acid phosphatase decrease Pap test negative readings? J Nat Cancer Inst 89 (1997), 1459.
11. O. Markovic, CAP-PAP Test for Cervical Cancer Screening, SBIR Phase-1 Report, in NIH-NCI-SBIR Phase-2 Grant Application "CAP-PAP Test for Cervical cancer Screening 2," SBIR Phase-2 Grantr, NIH #1R44CA86767-02.
12. O. Markovic, CAP-PAP Test for Cervical Cancer Screening 2,SBIR Phase-2 Grant Application, NIH #1R44CA86767-02.
13. O. Markovic, N. Markovic and M. Belledonne, Cervical Acid Phosphatase - Papanicolaou (CAP-PAP) Test, J Histotechnology 22 (1999), 43-47.
14. O. Markovic and N. Markovic, Acid phosphatase in cervical smears (CAP-PAP test), Arch Oncol 6 (1998), 137-139.
15. N. Markovic and O. Markovic, CAP-PAP Test Kit, USPTO Application No. 10/339,760 (January 2003).
16. N. Markovic, CAP-PAP Test for Specimens Collected in Solution, NIH-SBIR Grant #1R43CA94628-01.
17. N. Markovic, MARK-PAP Test Kit, SBIR-NIH Grant Application #1R43CA1017292-01.
18. B. Dawson-Saunders and R.G. Trapp, Basic & Clinical Biostatistics, Lange Medical Book, Norwalk CN, 1994, pp. 249-267.
19. MARK-PAP™ Technology Licensing Package, Executive Summary, BioSciCon, Rockville, MD, 2003.
20. S. Srivastava and J.A. Wagner, Surrogate endpoints in medicine, Disease Markers 18 (2002), 39-40.
21. T.C. Wright, T. Cox and S. Massad et al., for the 2001 ASCCP Consensus Conference. Consensus Statement: ASCCP 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities, JAMA 287 (2002), 2120-2129.
22. L.R. Rowe, C.J. Marshall and J.S. Bentz, One hundred percent thorough quality control rescreening of liquid-based monolayers in cervicovaginal cytopathology, Cancer 25:96(6) (2002), 325-329.
23. M. Arbyn and U. Schenck, Detection of false negative Pap smear by rapid reviewing. A meta-analysis, Acta Cytol. 44(6) (2000), 949-957.
24. Cervical Cancer. NIH Consensus Statement 1996 Apr 1-3;14(1):1-38.